N/A
N=67
TEE 3D RV Assessment for SAVR, Mini AVR, and TAVR
Right Ventricular Dysfunction
Bottom Line
View on ClinicalTrials.gov: NCT05804240 ↗Enrolled (actual)
67
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: 3D RVEF (Baseline) — 44.71; 48.74; 49.11 percentage — p=0.0167
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- 3D TEE RVEF (Diagnostic_test)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Thomas Jefferson University
- Primary completion
- Jun 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY 3D RVEF (Baseline) |
44.71; 48.74; 49.11 | 0.0167 sig |
| PRIMARY %Change in 3D RVEF (From Baseline to Postop) |
-8.36; -13.67; 4.51 | — |
| SECONDARY TAPSE (Baseline) |
14.09; 15.77; 15.45 | 0.0167 sig |
| SECONDARY RV FAC (Baseline) |
42.34; 48.37; 44.3 | 0.0167 sig |
| SECONDARY %Change in RV FAC (From Baseline to Postop) |
-9.49; -8.28; 4.35 | — |
| SECONDARY %Change in TAPSE (From Baseline to Postop) |
-32.48; -22.14; 10.46 | — |
Summary
Three-dimensional echocardiography has become a gold standard to assess right ventricular (RV) function, and investigators plan to use 3D transesophageal echocardiography to assess RV function in 3 types of aortic valve replacement (AVR): full sternotomy surgical AVR (full-SAVR), mini-sternotomy surgical AVR (mini-SAVR), and transcatheter AVR (TAVR).
Eligibility Criteria
Inclusion Criteria
- Adult patients over 18 years old
- Patients who had SAVR, mini AVR, or TAVR
Exclusion criteria
- Patients' refusal
- Suboptimal echocardiography data for RVEF, RV size, RIMP, RVFAC, TAPSE, S', STE
Data sourced from ClinicalTrials.gov (NCT05804240). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.